Aro can significantly enhance the activity of genetic medicines in extra-hepatic tissues by leveraging the Centyrin platform to enable tissue specific targeting
A common challenge across RNA and DNA based therapeutics is the inability to selectively target gene modulating therapies to diseased tissues. This lack of efficient, targeted delivery can lead to insufficient activity of the drug in tissues of interest and excessive toxicity in non-diseased tissues.
At Aro, we’re developing a patented platform technology called Centyrins that are uniquely positioned to achieve precise targeting of diverse therapeutic payloads to specific cells of interest. Our initial efforts are focused on discovering and developing Centyrin-oligonucleotide conjugate therapies that are meant to address one of the greatest challenges facing oligonucleotide-based medicines today: targeted delivery of oligonucleotides to extra-hepatic tissues.